MedTrace Logo

A Study of Safety and Immunogenicity of a Malaria Vaccine Candidate

NCT00284973 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2015-04-14

No results posted yet for this study

Summary

Shanghai Wanxing Bio-Pharmaceuticals is currently evaluating one malaria vaccine candidate, PfCP2.9 adjuvanted with Montanide ISA 720. This trial is designed to test the safety and immunogenicity of 3 doses and 2 vaccination schedules.

This blood stage candidate malaria vaccine is being developed for the routine immunization of infants and children living in malaria-endemic areas.

Conditions

  • Prophylaxis Against Plasmodium Falciparum Malaria

Interventions

BIOLOGICAL

Plasmodium falciparum Chimeric Prot. 2.9 - Montanide ISA 720

Sponsors & Collaborators

  • Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

    collaborator OTHER

  • Second Military Medical University

    collaborator OTHER

  • World Health Organization

    collaborator OTHER

  • PATH

    collaborator OTHER

  • Shanghai Wanxing Bio-Pharmaceutical Co. Ltd.

    lead INDUSTRY

Principal Investigators

  • Jinhong Hu, Dr. · Changhai Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-01-31

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00284973 on ClinicalTrials.gov